Xspray Pharma

Research update


Xspray Pharma: On the right track

Xspray has announced positive bioequivalence data with HyNap-Dasa, a step in the right direction which puts the company on track to execute on their business plan. We see the news as positive and indicative of news to come. With this report, we raise our Base Case to SEK 135 (120) per share. Our Bull and Bear Case remains at SEK 220 and 35 per share, respectively.

Continue reading (pdf) icon-download